Assessing coronary heart disease risk with traditional and novel risk factors

Area of Science:

• Cardiology and Preventive Medicine
• Biomarker Discovery and Validation

Background:

• Cardiovascular disease (CVD) is a primary cause of mortality globally.
• Established risk factors include age, hypertension, dyslipidemia, diabetes, and smoking.
• The Framingham calculation estimates 10-year coronary heart disease (CHD) risk to guide treatment.

Purpose of the Study:

• To evaluate the role of novel biomarkers in cardiovascular risk assessment.
• To determine if C-reactive protein (CRP) improves CHD risk prediction beyond traditional factors.
• To assess the utility of high-sensitivity CRP in identifying high-risk individuals, particularly those with normal low-density lipoprotein cholesterol (LDL-C).

Main Methods:

• Review of recent studies on cardiovascular risk markers.
• Analysis of the predictive value of lipoprotein(a), homocysteine, sitosterol, and CRP.
• Focus on high-sensitivity CRP (hs-CRP) in relation to Framingham risk scores and LDL-C levels.

Main Results:

• Elevated levels of lipoprotein(a), homocysteine, sitosterol, and CRP are associated with increased CHD risk.
• High-sensitivity CRP identifies high-risk patients who may not have elevated LDL-C.
• CRP adds predictive value to existing Framingham risk functions for CHD.

Conclusions:

• High-sensitivity CRP is a valuable addition to traditional risk factors for CHD assessment.
• Integrating CRP improves the identification of individuals requiring intervention, especially in lipid management.
• Global risk assessment, incorporating markers like CRP, is crucial for determining appropriate LDL-C target goals.